The data presented in our study, however, shows that an anti-VCAM-1 mAb specific to domain 2 and not domain 1– 3H4 mAb –was able to reduce monocyte adhesion (Fig. 2 and Fig. 4) and transmigration (Fig. 6 and Fig. 7) using in vitro models of early atherosclerosis. This evidence concerns the gene VCAM1 and atherosclerosis.